Gilberto Moreno Bonilla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gilberto Moreno Bonilla has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Simon Lee
The Skin Hospital Westmead New South Wales Australia
7 shared publications- Marjia Johns
The Skin Hospital Westmead New South Wales Australia
4 shared publications - Pablo Fernández-Peñas
Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
3 shared publications - Thomas Jonathan Stewart
Department of Dermatology Westmead Hospital Westmead New South Wales Australia
3 shared publications - Ana Isabel Rodríguez Bandera
Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain
2 shared publications James Elhindi
Research and Education Network, Western Sydney Local Health District Westmead New South Wales Australia
2 shared publications
Latest Publications
- 29 September 2026
- Published by Wiley in Australasian Journal of Dermatology
Seasonal Variation in Skin Cancer Presentation in Primary Care Clinic in Parramatta, NSW
Background: Seasonal variation in melanoma and keratinocyte cancer (KC) diagnoses has been noted in the literature, predominantly from northern hemisphere populations, with summer peaks most commonly noted. There is limited contemporary literature from Australian data. This is the first study to our knowledge to examine both melanoma and KC presentations in Australia, and the first to investigate this in a primary care setting. Methods: A retrospective study was performed based on histopathological data taken from a primary care clinic in Parramatta NSW between March 2016 and March 2025. Inclusion criteria were basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. Multiple complementary analytical approaches were performed, including cosinor harmonic regression, negative binomial models, mixed‐effects models, time series decomposition, and Bayesian inference. Multiple sensitivity analyses were also performed to assess the robustness of the findings. Results: 9778 skin cancers were included over a nine‐year period, which included BCC; ( n = 5290; 54.1%), SCC; ( n = 4041; 41.3%), and melanoma ( n = 447; 4.6%). Seasonal differences were statistically significant; however, clinically negligible. Conversely, there was a demonstrated reduction in presentations at the onset of COVID‐19, with sustained reduction in presentations through to 2024. Discussion: No clinically significant seasonal variation in skin cancer presentations was found, in direct contrast with literature from the northern hemisphere. This may reflect Australia's milder climate and relatively high annual ultraviolet index, effective public health messaging, and the accessibility of primary care services. Deficits in presentations throughout the year appear operation‐dependent as opposed to biological seasonality. The significant and sustained impact of COVID‐19 on skin cancer presentation raises concerns regarding the ongoing impact of delayed diagnoses of skin cancer in the Australian population. Conclusion: No clinically significant seasonal variation in skin cancer presentation was found in a large primary care skin cancer cohort in metropolitan Sydney; however, COVID‐19 exerts a substantial and sustained impact. Vigilance regarding the long‐term consequences of pandemic‐related healthcare disruptions is warranted.
- 29 September 2026
- Published by Wiley in Australasian Journal of Dermatology
Seasonal Variation in Skin Cancer Presentation in Primary Care Clinic in Parramatta, NSW
Background: Seasonal variation in melanoma and keratinocyte cancer (KC) diagnoses has been noted in the literature, predominantly from northern hemisphere populations, with summer peaks most commonly noted. There is limited contemporary literature from Australian data. This is the first study to our knowledge to examine both melanoma and KC presentations in Australia, and the first to investigate this in a primary care setting. Methods: A retrospective study was performed based on histopathological data taken from a primary care clinic in Parramatta NSW between March 2016 and March 2025. Inclusion criteria were basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. Multiple complementary analytical approaches were performed, including cosinor harmonic regression, negative binomial models, mixed‐effects models, time series decomposition, and Bayesian inference. Multiple sensitivity analyses were also performed to assess the robustness of the findings. Results: 9778 skin cancers were included over a nine‐year period, which included BCC; ( n = 5290; 54.1%), SCC; ( n = 4041; 41.3%), and melanoma ( n = 447; 4.6%). Seasonal differences were statistically significant; however, clinically negligible. Conversely, there was a demonstrated reduction in presentations at the onset of COVID‐19, with sustained reduction in presentations through to 2024. Discussion: No clinically significant seasonal variation in skin cancer presentations was found, in direct contrast with literature from the northern hemisphere. This may reflect Australia's milder climate and relatively high annual ultraviolet index, effective public health messaging, and the accessibility of primary care services. Deficits in presentations throughout the year appear operation‐dependent as opposed to biological seasonality. The significant and sustained impact of COVID‐19 on skin cancer presentation raises concerns regarding the ongoing impact of delayed diagnoses of skin cancer in the Australian population. Conclusion: No clinically significant seasonal variation in skin cancer presentation was found in a large primary care skin cancer cohort in metropolitan Sydney; however, COVID‐19 exerts a substantial and sustained impact. Vigilance regarding the long‐term consequences of pandemic‐related healthcare disruptions is warranted.
- 26 January 2026
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (1) , 24-27
Frozen Section Mohs Micrographic Surgery for Dermatofibrosarcoma Protuberans—A Case Series of 38 Patients in NSW , Australia
Background: Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous tumour with a locally infiltrative growth pattern that has high rates of recurrence. Mohs micrographic surgery is recommended as the gold‐standard treatment over wide local excision (WLE) due to tissue‐sparing and reduced recurrence rates. No previous data on surgical outcomes following Mohs Micrographic Surgery (MMS) for DFSP have been reported in Australia to date. This study aims to review the outcomes of DFSP treated with frozen‐section MMS across three centres in New South Wales (NSW), Australia, and compare these outcomes with those in the current literature. Methods: A retrospective review of patients who underwent MMS for DFSP between 2010 and 2023 was performed. Patient demographics, histological findings, surgical treatment and follow‐up data were collected. Recurrence was assessed through electronic medical records, clinical assessments by a dermatologist or general practitioner, and patient self‐report. Results: In all, 38 cases of DFSP were included (27 female, 11 male; median age 39 years, range 16–64). The trunk was the most common site. Clinical margins and Mohs stages were recorded in 37 of 38 cases, with 73% of cases cleared with clinical margins of ≤ 20 mm. Clinical or self‐reported follow‐up was available for 28 of 38 patients (73.6%) over a mean of 51 months (range, 5–132 months). No local recurrences were identified during this period. Conclusion: This is the first Australian case series on MMS for DFSP. Our findings demonstrate no recurrences with follow‐up and demonstrate that MMS may achieve clearance with smaller clinical margins than WLE. These results support international guidelines recommending MMS as the gold‐standard treatment and highlight the need to improve access to MMS in Australia.
- 26 January 2026
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (1) , 24-27
Frozen Section Mohs Micrographic Surgery for Dermatofibrosarcoma Protuberans—A Case Series of 38 Patients in NSW , Australia
Background: Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous tumour with a locally infiltrative growth pattern that has high rates of recurrence. Mohs micrographic surgery is recommended as the gold‐standard treatment over wide local excision (WLE) due to tissue‐sparing and reduced recurrence rates. No previous data on surgical outcomes following Mohs Micrographic Surgery (MMS) for DFSP have been reported in Australia to date. This study aims to review the outcomes of DFSP treated with frozen‐section MMS across three centres in New South Wales (NSW), Australia, and compare these outcomes with those in the current literature. Methods: A retrospective review of patients who underwent MMS for DFSP between 2010 and 2023 was performed. Patient demographics, histological findings, surgical treatment and follow‐up data were collected. Recurrence was assessed through electronic medical records, clinical assessments by a dermatologist or general practitioner, and patient self‐report. Results: In all, 38 cases of DFSP were included (27 female, 11 male; median age 39 years, range 16–64). The trunk was the most common site. Clinical margins and Mohs stages were recorded in 37 of 38 cases, with 73% of cases cleared with clinical margins of ≤ 20 mm. Clinical or self‐reported follow‐up was available for 28 of 38 patients (73.6%) over a mean of 51 months (range, 5–132 months). No local recurrences were identified during this period. Conclusion: This is the first Australian case series on MMS for DFSP. Our findings demonstrate no recurrences with follow‐up and demonstrate that MMS may achieve clearance with smaller clinical margins than WLE. These results support international guidelines recommending MMS as the gold‐standard treatment and highlight the need to improve access to MMS in Australia.
- 14 January 2026
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (3) , 169-175
Primary Vulvovaginal Melanoma: A Fifteen‐Year Multidisciplinary Team Experience
Vulvovaginal melanoma is a rare malignancy with a poor prognosis and variable clinical presentation. In a 15‐year retrospective review, we identified 15 cases where wide local excision was the most common treatment. Serial digital photography was implemented to support early detection, monitoring and clinician education.
- 14 January 2026
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (3) , 169-175
Primary Vulvovaginal Melanoma: A Fifteen‐Year Multidisciplinary Team Experience
Vulvovaginal melanoma is a rare malignancy with a poor prognosis and variable clinical presentation. In a 15‐year retrospective review, we identified 15 cases where wide local excision was the most common treatment. Serial digital photography was implemented to support early detection, monitoring and clinician education.
- 30 December 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (2)
Factors to Predict 13 or More Sections in Mohs Micrographic Surgery
Background/Objectives: Studies on factors that predict the number of stages in Mohs micrographic surgery (MMS) have been published previously. To date, no studies have analysed the predictors for the number of sections during MMS. Methods: A retrospective case–control study of patients treated for keratinocyte cancer (KC) between 2013 and 2017 was conducted to identify predictive factors for 13 or more MMS sections. Patient, tumour, management and practitioner‐related factors were analysed with univariate logistic regression and a multivariate predictive model. Surface area for tumours and defects was studied in cases and controls as a secondary outcome. Results: Out of 10,132 tumours, a total of 195 cases representing 1.9% of all MMS procedures for the study period required more than 13 MMS sections. A control group with 213 tumours was also randomly selected. Largest preoperative tumour diameter, mixed histology, tumour recurrence and age were significant predictors for 13 or more MMS sections in a multivariate model (AUC 88.4%, sensitivity 77.2% and specificity 87.0%). Significantly larger defects were also found in our cases compared to the control group (median tumour to defect ratio 3.94 vs. 2.43; p < 0.0001). Conclusion: Identifying factors that predict 13 or more sections prior to surgery could assist the Mohs practitioner in informing patients and allocating time and resources accordingly.
- 30 December 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (2)
Factors to Predict 13 or More Sections in Mohs Micrographic Surgery
Background/Objectives: Studies on factors that predict the number of stages in Mohs micrographic surgery (MMS) have been published previously. To date, no studies have analysed the predictors for the number of sections during MMS. Methods: A retrospective case–control study of patients treated for keratinocyte cancer (KC) between 2013 and 2017 was conducted to identify predictive factors for 13 or more MMS sections. Patient, tumour, management and practitioner‐related factors were analysed with univariate logistic regression and a multivariate predictive model. Surface area for tumours and defects was studied in cases and controls as a secondary outcome. Results: Out of 10,132 tumours, a total of 195 cases representing 1.9% of all MMS procedures for the study period required more than 13 MMS sections. A control group with 213 tumours was also randomly selected. Largest preoperative tumour diameter, mixed histology, tumour recurrence and age were significant predictors for 13 or more MMS sections in a multivariate model (AUC 88.4%, sensitivity 77.2% and specificity 87.0%). Significantly larger defects were also found in our cases compared to the control group (median tumour to defect ratio 3.94 vs. 2.43; p < 0.0001). Conclusion: Identifying factors that predict 13 or more sections prior to surgery could assist the Mohs practitioner in informing patients and allocating time and resources accordingly.
- 22 November 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (1) , 18-23
Ten Years of Scalp Keratinocyte Carcinomas (Basal Cell Carcinomas and Squamous Cell Carcinomas) Treated by Mohs Micrographic Surgery at a Large Australian Centre, a Descriptive Study
Background: There is a paucity of data on scalp keratinocyte carcinomas (KCs) referred for Mohs micrographic surgery (MMS). This study aimed to perform a descriptive analysis of scalp KCs—specifically basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs)—treated with MMS at The Skin Hospital in Sydney, Australia. Methods: We performed a retrospective analysis of all scalp KCs treated with MMS from October 2012 to September 2022 from an electronic database. Extracted data included age, sex, tumour histology and aggressiveness, anatomical location, preoperative tumour size, final defect size, number of MMS stages and sections, extensive subclinical spread and repair method. Results: We identified 1177 scalp KCs treated with MMS in 889 patients, consisting of 948 BCCs (80.5%) and 229 SCCs (19.5%). The median age of patients with BCCs was significantly younger (60 years) than that of SCCs (73 years) ( p < 0.001). SCCs were more commonly found in males (182/229, 79%) ( p < 0.001). The majority of KCs were located on the frontal scalp (948/1177, 55%). BCCs were more likely to be of an aggressive subtype (58%, 512/876) than SCCs (21%, 44/212) ( p < 0.001). The median largest tumour and defect diameter was larger for SCCs than for BCCs ( p < 0.001). There was no significant difference in the median number of MMS stages for tumour type ( p = 0.121). Extensive subclinical spread was more common for aggressive SCCs (13/44, 29.5%) than for BCCs (84/511, 16.4%) ( p = 0.028). Primary closure repair was most common (55%, 644/1177). Conclusion: The observed differences in patient, tumour and treatment characteristics may help inform clinical practice and inspire further research.
- 22 November 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (1) , 18-23
Ten Years of Scalp Keratinocyte Carcinomas (Basal Cell Carcinomas and Squamous Cell Carcinomas) Treated by Mohs Micrographic Surgery at a Large Australian Centre, a Descriptive Study
Background: There is a paucity of data on scalp keratinocyte carcinomas (KCs) referred for Mohs micrographic surgery (MMS). This study aimed to perform a descriptive analysis of scalp KCs—specifically basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs)—treated with MMS at The Skin Hospital in Sydney, Australia. Methods: We performed a retrospective analysis of all scalp KCs treated with MMS from October 2012 to September 2022 from an electronic database. Extracted data included age, sex, tumour histology and aggressiveness, anatomical location, preoperative tumour size, final defect size, number of MMS stages and sections, extensive subclinical spread and repair method. Results: We identified 1177 scalp KCs treated with MMS in 889 patients, consisting of 948 BCCs (80.5%) and 229 SCCs (19.5%). The median age of patients with BCCs was significantly younger (60 years) than that of SCCs (73 years) ( p < 0.001). SCCs were more commonly found in males (182/229, 79%) ( p < 0.001). The majority of KCs were located on the frontal scalp (948/1177, 55%). BCCs were more likely to be of an aggressive subtype (58%, 512/876) than SCCs (21%, 44/212) ( p < 0.001). The median largest tumour and defect diameter was larger for SCCs than for BCCs ( p < 0.001). There was no significant difference in the median number of MMS stages for tumour type ( p = 0.121). Extensive subclinical spread was more common for aggressive SCCs (13/44, 29.5%) than for BCCs (84/511, 16.4%) ( p = 0.028). Primary closure repair was most common (55%, 644/1177). Conclusion: The observed differences in patient, tumour and treatment characteristics may help inform clinical practice and inspire further research.
- 21 October 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (8)
Mohs Micrographic Surgery in the Australian Public Health System: A Retrospective Observational Study and Review of the Australian Literature
Background/Objectives: Mohs micrographic surgery (MMS) is integral to skin cancer management due to its benefits in margin control and tissue conservation. In Australia, it is predominantly performed in the private setting, with Royal North Shore Hospital being the sole provider in the public system. This study presented an analysis of MMS within the Australian public health system and a review of local literature. Methods: Conducting a retrospective chart review, we examined patients undergoing MMS between January 2018 and December 2022. Data encompassed patient demographics, tumour characteristics and surgical outcomes. Four electronic databases were searched for Australian literature on MMS. Results: A total of 344 MMS procedures involving 299 patients were conducted at Royal North Shore Hospital. Patients averaging 66.4 years of age (range 19–92 years) predominantly presented with basal cell carcinomas (92.2%) and squamous cell carcinomas (6.4%). 98.2% of tumours were found on the head and neck, genitalia, hands, digits and below the knee. The mean [standard deviation (SD)], pre‐operative tumour and defect sizes were 1.75 cm [SD 1.01] and 2.30 cm [SD 1.35] in maximum diameter, respectively. Our tumour and defect sizes were smaller compared to MMS procedures conducted in the public system 30 years ago. Review of local literature resulted in 11 relevant studies, of which 10 came from the private setting. Conclusions: This study provided crucial insights into MMS referral patterns, utilisation and outcomes, demonstrating that the use of MMS aligns with local and international best practice.
- 21 October 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (8)
Mohs Micrographic Surgery in the Australian Public Health System: A Retrospective Observational Study and Review of the Australian Literature
Background/Objectives: Mohs micrographic surgery (MMS) is integral to skin cancer management due to its benefits in margin control and tissue conservation. In Australia, it is predominantly performed in the private setting, with Royal North Shore Hospital being the sole provider in the public system. This study presented an analysis of MMS within the Australian public health system and a review of local literature. Methods: Conducting a retrospective chart review, we examined patients undergoing MMS between January 2018 and December 2022. Data encompassed patient demographics, tumour characteristics and surgical outcomes. Four electronic databases were searched for Australian literature on MMS. Results: A total of 344 MMS procedures involving 299 patients were conducted at Royal North Shore Hospital. Patients averaging 66.4 years of age (range 19–92 years) predominantly presented with basal cell carcinomas (92.2%) and squamous cell carcinomas (6.4%). 98.2% of tumours were found on the head and neck, genitalia, hands, digits and below the knee. The mean [standard deviation (SD)], pre‐operative tumour and defect sizes were 1.75 cm [SD 1.01] and 2.30 cm [SD 1.35] in maximum diameter, respectively. Our tumour and defect sizes were smaller compared to MMS procedures conducted in the public system 30 years ago. Review of local literature resulted in 11 relevant studies, of which 10 came from the private setting. Conclusions: This study provided crucial insights into MMS referral patterns, utilisation and outcomes, demonstrating that the use of MMS aligns with local and international best practice.
- 8 July 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (6) , e361-e364
Intravascular Basal Cell Carcinoma During Mohs Surgery
Intravascular invasion of basal cell carcinoma is an exceedingly rare finding during Mohs' micrographic surgery. We present three cases and discuss its significance and management implications.
- 8 July 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (6) , e361-e364
Intravascular Basal Cell Carcinoma During Mohs Surgery
Intravascular invasion of basal cell carcinoma is an exceedingly rare finding during Mohs' micrographic surgery. We present three cases and discuss its significance and management implications.
- 4 June 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (5) , 258-267
Mohs Micrographic Surgery for Basal Cell Carcinoma: Predictive Factors for Increased Stages and Relative Defect Sizes
Keratinocyte cancers (KCs), including basal cell carcinomas (BCCs), are the most common cancers in Australia. While Mohs micrographic surgery (MMS) is the gold standard treatment, it can be resource intensive, particularly for cases requiring multiple stages. This study aimed to identify predictors of increased MMS stages and a greater tumour‐to‐defect size discrepancy in head and neck BCC. A retrospective analysis of the Mohs Electronic Database at the Skin Hospital's Westmead and Darlinghurst sites in Sydney, Australia was conducted from October 2012 to December 2022, including 18,346 BCC cases. The main outcomes were the number of MMS stages and the relative defect size, with covariates including patient age, sex, tumour characteristics and Mohs specialist factors. Older patients required more stages (1.65 vs. 1.90; p < 0.01) and had larger relative defect sizes (2.10 vs. 2.90; p < 0.01). Larger tumours required more stages (1.69 vs. 1.94; p < 0.01), while smaller tumours had disproportionately larger relative defects (5.94 vs. 2.08; p < 0.01). Nodular BCC required fewer stages (1.63; p < 0.01) and had the smallest defects (2.11; p < 0.01). Notably, superficial BCCs required a similar number of MMS stages as traditionally aggressive subtypes. Tumours of the ear, eye and nose required more stages than other cosmetic units (2.05, 2.02, 1.94; p < 0.01). Increased Mohs experience reduced the number of stages (2.18 vs. 1.83; p = 0.03) and relative defect sizes (3.49 vs. 2.50; p < 0.01). Patient age, tumour size, subtype, cosmetic unit and Mohs specialist experience influence MMS stages and relative defect sizes in head and neck BCC. Recognising these factors can enhance surgical planning, personalise treatment strategies and improve patient outcomes.
- 4 June 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (5) , 258-267
Mohs Micrographic Surgery for Basal Cell Carcinoma: Predictive Factors for Increased Stages and Relative Defect Sizes
Keratinocyte cancers (KCs), including basal cell carcinomas (BCCs), are the most common cancers in Australia. While Mohs micrographic surgery (MMS) is the gold standard treatment, it can be resource intensive, particularly for cases requiring multiple stages. This study aimed to identify predictors of increased MMS stages and a greater tumour‐to‐defect size discrepancy in head and neck BCC. A retrospective analysis of the Mohs Electronic Database at the Skin Hospital's Westmead and Darlinghurst sites in Sydney, Australia was conducted from October 2012 to December 2022, including 18,346 BCC cases. The main outcomes were the number of MMS stages and the relative defect size, with covariates including patient age, sex, tumour characteristics and Mohs specialist factors. Older patients required more stages (1.65 vs. 1.90; p < 0.01) and had larger relative defect sizes (2.10 vs. 2.90; p < 0.01). Larger tumours required more stages (1.69 vs. 1.94; p < 0.01), while smaller tumours had disproportionately larger relative defects (5.94 vs. 2.08; p < 0.01). Nodular BCC required fewer stages (1.63; p < 0.01) and had the smallest defects (2.11; p < 0.01). Notably, superficial BCCs required a similar number of MMS stages as traditionally aggressive subtypes. Tumours of the ear, eye and nose required more stages than other cosmetic units (2.05, 2.02, 1.94; p < 0.01). Increased Mohs experience reduced the number of stages (2.18 vs. 1.83; p = 0.03) and relative defect sizes (3.49 vs. 2.50; p < 0.01). Patient age, tumour size, subtype, cosmetic unit and Mohs specialist experience influence MMS stages and relative defect sizes in head and neck BCC. Recognising these factors can enhance surgical planning, personalise treatment strategies and improve patient outcomes.
- Open Access
- 24 August 2023
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 64 (4) , 497-503
Slice by slice: An Australian state‐by‐state analysis of Mohs micrographic surgery over 5 years
Background: In November 2018, Mohs micrographic surgery (MMS) was restricted to fellows registered with the Australasian College of Dermatologists. Three new item numbers for the provision of MMS were also introduced. We examine the national and state usage of MMS item numbers based on Medicare claim statistics and Mohs surgeons' self-reported data, noting the impact of the pandemic and the usage of individual item numbers.Methods: Medicare item number data were obtained from the Medicare Benefits Schedule website for January 2017-December 2021. Self-reported data were collected on an annual basis by the Royal College of Pathologists of Australasia (RCPA) as part of the Quality Assurance Program (QAP) from 2019 onwards. Data were analysed with the Holt-Winters smoothing method for forecasting.Results: An increasing number of MMS claims were processed each year, with a total of 89,183 for the study period. Since November 2018, 97.7% of procedures have been conducted on the head, neck, genitalia, hand, digits, leg (below the knee) or foot. The provision of services across the country was maintained during the pandemic years of 2020-2021, with an increase in services in Queensland. There were discrepancies between the states for procedures performed in greater than six sections; these constituted more than 35% of claims in Queensland and Western Australia compared to less than 15% in other states. The pandemic impacted certain states more than others, with Victoria and the Northern Territory having significantly fewer presentations than predicted (p < 0.05).Conclusions: Overall, the use of MMS in Australia is in keeping with peer-developed guidelines, despite discrepancies between states. Although certain states were more severely affected by the pandemic, MMS is increasingly used in Australia.
- 24 August 2023
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 64 (4) , 497-503
Open AccessSlice by slice: An Australian state‐by‐state analysis of Mohs micrographic surgery over 5 years
Background: In November 2018, Mohs micrographic surgery (MMS) was restricted to fellows registered with the Australasian College of Dermatologists. Three new item numbers for the provision of MMS were also introduced. We examine the national and state usage of MMS item numbers based on Medicare claim statistics and Mohs surgeons' self-reported data, noting the impact of the pandemic and the usage of individual item numbers.Methods: Medicare item number data were obtained from the Medicare Benefits Schedule website for January 2017-December 2021. Self-reported data were collected on an annual basis by the Royal College of Pathologists of Australasia (RCPA) as part of the Quality Assurance Program (QAP) from 2019 onwards. Data were analysed with the Holt-Winters smoothing method for forecasting.Results: An increasing number of MMS claims were processed each year, with a total of 89,183 for the study period. Since November 2018, 97.7% of procedures have been conducted on the head, neck, genitalia, hand, digits, leg (below the knee) or foot. The provision of services across the country was maintained during the pandemic years of 2020-2021, with an increase in services in Queensland. There were discrepancies between the states for procedures performed in greater than six sections; these constituted more than 35% of claims in Queensland and Western Australia compared to less than 15% in other states. The pandemic impacted certain states more than others, with Victoria and the Northern Territory having significantly fewer presentations than predicted (p < 0.05).Conclusions: Overall, the use of MMS in Australia is in keeping with peer-developed guidelines, despite discrepancies between states. Although certain states were more severely affected by the pandemic, MMS is increasingly used in Australia.
- 10 July 2019
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 61 (1) , 85-87
Increased collaboration between Mohs and plastic surgeons in the surgical management of skin cancer in Australia
- 10 July 2019
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 61 (1) , 85-87
Increased collaboration between Mohs and plastic surgeons in the surgical management of skin cancer in Australia